254 related articles for article (PubMed ID: 25605023)
1. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.
Johnson DP; Spitz GS; Tharkar S; Quayle SN; Shearstone JR; Jones S; McDowell ME; Wellman H; Tyler JK; Cairns BR; Chandrasekharan MB; Bhaskara S
Oncotarget; 2015 Mar; 6(7):4863-87. PubMed ID: 25605023
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase 1 (HDAC1) Negatively Regulates Thermogenic Program in Brown Adipocytes via Coordinated Regulation of Histone H3 Lysine 27 (H3K27) Deacetylation and Methylation.
Li F; Wu R; Cui X; Zha L; Yu L; Shi H; Xue B
J Biol Chem; 2016 Feb; 291(9):4523-36. PubMed ID: 26733201
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
4. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
5. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
6. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
8. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
9. EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
Adamik J; Jin S; Sun Q; Zhang P; Weiss KR; Anderson JL; Silbermann R; Roodman GD; Galson DL
Mol Cancer Res; 2017 Apr; 15(4):405-417. PubMed ID: 28119431
[TBL] [Abstract][Full Text] [Related]
10. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
13. Essential roles of HDAC1 and 2 in lineage development and genome-wide DNA methylation during mouse preimplantation development.
Zhao P; Wang H; Wang H; Dang Y; Luo L; Li S; Shi Y; Wang L; Wang S; Mager J; Zhang K
Epigenetics; 2020 Apr; 15(4):369-385. PubMed ID: 31533525
[TBL] [Abstract][Full Text] [Related]
14. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A.
Tonini T; Bagella L; D'Andrilli G; Claudio PP; Giordano A
Oncogene; 2004 Jun; 23(28):4930-7. PubMed ID: 15077161
[TBL] [Abstract][Full Text] [Related]
15. HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation.
Nalawansha DA; Gomes ID; Wambua MK; Pflum MKH
Cell Chem Biol; 2017 Apr; 24(4):481-492.e5. PubMed ID: 28392145
[TBL] [Abstract][Full Text] [Related]
16. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
17. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
Bradley WD; Arora S; Busby J; Balasubramanian S; Gehling VS; Nasveschuk CG; Vaswani RG; Yuan CC; Hatton C; Zhao F; Williamson KE; Iyer P; Méndez J; Campbell R; Cantone N; Garapaty-Rao S; Audia JE; Cook AS; Dakin LA; Albrecht BK; Harmange JC; Daniels DL; Cummings RT; Bryant BM; Normant E; Trojer P
Chem Biol; 2014 Nov; 21(11):1463-75. PubMed ID: 25457180
[TBL] [Abstract][Full Text] [Related]
18. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
19. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining.
Miller KM; Tjeertes JV; Coates J; Legube G; Polo SE; Britton S; Jackson SP
Nat Struct Mol Biol; 2010 Sep; 17(9):1144-51. PubMed ID: 20802485
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Yamaguchi J; Sasaki M; Sato Y; Itatsu K; Harada K; Zen Y; Ikeda H; Nimura Y; Nagino M; Nakanuma Y
Cancer Sci; 2010 Feb; 101(2):355-62. PubMed ID: 19860841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
